SymBio Pharmaceuticals Limited announced non-consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported net sales of JPY 1,611,458,000 as compared to JPY 888,229,000 a year ago. Operating loss was JPY 595,948,000 as compared to JPY 714,524,000 a year ago. Ordinary loss was JPY 616,009,000 as compared to JPY 748,913,000 a year ago. Net loss was JPY 616,959,000 as compared to JPY 759,692,000 a year ago. Net loss per share were JPY 7.48 as compared to JPY 13.28 a year ago. Loss before income taxes was JPY 616,959,000 as compared to JPY 758,742,000 a year ago.

The company provided earnings results guidance for the fiscal year ending December 31, 2019. For the year, the company expects net sales of JPY 4,465 million, operating loss of JPY 3,587 million, ordinary loss of JPY 3,612 million, net loss of JPY 3,616 million and net loss per share of JPY 43.88.